(TEAR, BLRX, PLCM) CRWENewswire Stocks In Action BioLineRx Ltd -BLRX - reported that it has signed a worldwide, exclusive license agreement with Genoscience, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. On its Fourth quarter fiscal 2011, Polycom Inc - PLCM - posted record consolidated net revenues of $407 million, compared to $340 million in the same period the prior year.
